Equity Research Surgical & Medical Instruments & Apparatus

Should You Buy Pulmonx Corporation Stock in 2026?

By CirclFi Research Team · · 11/13 models active

According to the CirclFi Deep Alpha Valuation Engine, Pulmonx Corporation (LUNG) occupies a solid middle-ground position with a Quality of Company score of 7.5/10. At the current market price of $1.27, the investment case depends heavily on whether our 13 independent valuation models indicate a discount to fair value.

The short answer: 10 of 11 CirclFi valuation models project upside for Pulmonx Corporation (LUNG) at $1.27 — the model consensus leans bullish, with a Quality Score of 7.5/10 and Value-Trap risk of 12/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.

Key Takeaways

  • 10 of 11 models see upside — majority bullish
  • Quality Score: 7.5/10 — Strong — above-average quality
  • Value Trap Risk: 12/100 — Minimal — healthy fundamentals
  • Fair Value Range: $0.50 – $4.49 (791% spread)

Bullish Models

10 / 11

Bearish Models

1 / 11

Quality Score

7.5 /10

Strong — above-average quality

Value Trap Risk

12 /100
Minimal

Minimal — healthy fundamentals

Model Consensus

11 /13
Active Models

Avg. confidence: 27%

Investment Thesis

The Bull Case

Target: $4.49 (+253.7% upside)

  • According to the CirclFi Quality of Company (QOC) framework, Pulmonx Corporation's score of 7.5/10 reflects durable competitive advantages that should sustain earnings power through market cycles.
  • According to the CirclFi Deep Alpha Valuation Engine, the stock shows multi-model upside with an average implied return of +119.2% across 10 bullish models from the current price of $1.27.
  • According to the CirclFi Deep Alpha Valuation Engine, the EROIC Spread model targets a fair value of $4.49 (+253.7%), anchoring the bull case with a methodology that provides a differentiated analytical lens.

The Bear Case

Target: $0.50 (-60.3%)

  • According to the CirclFi Deep Alpha Valuation Engine, the Bayesian DCF model sees the stock as overvalued with a fair value of $0.50 (-60.3%), suggesting that the market price embeds overly optimistic growth assumptions.
  • According to the CirclFi Deep Alpha Valuation Engine, the wide model spread of +314.0% reflects fundamental divergence on key assumptions (growth, cost of capital) depending on the methodology.

Peer Benchmarking

DXCM DexCom, Inc.
10.0
IRMD iRadimed Corporation
10.0
PODD Insulet Corporation
10.0
RMD ResMed Inc.
10.0
WST West Pharmaceutical
9.9

See full Surgical & Medical Instruments & Apparatus rankings →

Valuation Divergence

Spread

791%

Fair Value Range

$0.50 – $4.49

A 791% spread signals high uncertainty. The investment outcome depends heavily on which scenario plays out.

Most Bullish

EROIC

$4.49 (+253.7%)

Most Bearish

Bayesian DCF

$0.50 (-60.3%)

Key Risk Factors

Model Disagreement

791% spread signals high variance in projections.

Macro/Sector Risk

Surgical & Medical Instruments & Apparatus headwinds could affect earnings trajectory.

Model Limitations

Backward-looking models cannot predict disruptions.

Want the full 13-model breakdown?

See every fair value, confidence score, and value trap analysis.

View LUNG Data Page →

The Bottom Line

The convergence of 7.5/10 quality, multi-model undervaluation (10/11 bullish, +119.2% avg. upside), and a composite fair value of $2.78 vs. $1.27 current price makes Pulmonx Corporation one of the more compelling opportunities in our coverage. As always, our models provide a quantitative starting point — not a substitute for individual due diligence.

These are quantitative model outputs, not investment recommendations. Pulmonx Corporation's future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →

Frequently Asked Questions

Should I buy LUNG stock right now?

Based on CirclFi's multi-model analysis, 10 of 11 models see upside for LUNG at $1.27. The majority of models suggest the stock trades below fair value, but investors should weigh this against the Quality Score of 7.5/10 and individual risk tolerance. This is not a buy recommendation — see our full disclaimer.

What are the biggest risks of investing in Pulmonx Corporation?

Key risks include: wide model disagreement (791% spread), signaling high uncertainty; general market and sector-specific risks affecting Surgical & Medical Instruments & Apparatus companies. Always diversify and consult a financial advisor.

How does LUNG compare to its competitors?

Among Surgical & Medical Instruments & Apparatus peers, LUNG holds a Quality Score of 7.5/10. Comparable companies include DXCM (QOC 10.0), IRMD (QOC 10.0), PODD (QOC 10.0). The relative ranking helps investors identify whether LUNG offers better fundamental quality than alternatives in the same sector.

Is LUNG a good long-term investment?

Long-term investment potential depends on fundamental quality and sustainable competitive advantages. LUNG's Quality Score of 7.5/10 is encouraging for long-term holders, indicating consistent profitability, manageable debt, and healthy cash flows. Check our full data page for all 13 model estimates.

What price should I buy LUNG at?

CirclFi does not provide target buy prices or price alerts. However, our 11 active models produce fair value estimates ranging from $0.50 to $4.49. At $1.27, the stock trades within the range of model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.

Want the complete picture?

See all 13 model estimates, confidence scores, and the full valuation table for LUNG.

View LUNG Data Page Full Terminal — $39/mo

Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →